2021-07-12 by Proactive Australia Anteris Technologies Ltd (ASX:AVR) has achieved a breakthrough in manufacturing the tissue used in ADAPT® treated products from bovine pericardium, after developing specialised machinery to create consistently thin tissue through an innovative processing technique. This process reduces the native pericardia thickness to yield tissue with the desired thickness to make its 3D single-piece aortic valves. Valve durability studies Anteris says thinning tissue on-demand is a challenging engineering feat, which is achieved by several custom equipment iterations and parameter adjustments. Tissue tests demonstrated tensile strength properties equivalent to current ADAPT® treated pericardia. Valve durability studies proving absolute equivalence between the processed tissue and native (thin) tissue are the confirmatory next step.